1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Cystic Fibrosis Market in Europe 2015-2019

Cystic Fibrosis Sector: Forecast until 2019 in Europe

  • February 2015
  • 113 pages
  • ID: 2681252
In this report:
April 2014: Net revenue increases ##.## percent to US$##.## billion in the first quarter of 2014 April 2014: Launches its headquarters at Singapore in the APAC region March 2014: Actavis and Valeant announce the FDA Approval for Metronidazole ##.## percent
The Cystic Fibrosis market in Europe was valued at US$##,##.## million in 2014 and is expected to reach US$##,##.## million by 2019, growing at a CAGR of ##.## percent.

Summary

Table of Contents

Search Inside

About Cystic Fibrosis

Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited disease. The primary symptoms of cystic fibrosis contain high salt content in the sweat, breathing difficulties, secretion of abnormally viscous mucus, respiratory complications, difficulties associated to digestion, and growth anomalies. Cystic fibrosis is one of the most frequent genetic disorders observed in Caucasian children. Rare diseases are those that affect less than 5 patients per 10,000, as defined in the EU by Rare Disease UK. Cystic fibrosis is therefore classified under rare diseases. The incidence of cystic fibrosis varies between populations. It is significantly less frequent in Asian and African populations compared to Caucasians (people from EU, North America continent, and Australasia), with a marked difference between each country in those regions. Precise data concerning the prevalence of cystic fibrosis in Europe (EU) is not available, but it is projected to be 1 in 8,000-10,000 individuals. Cystic fibrosis is a chronic disease and is usually progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or, rarely, at birth. The principal manifestations of cystic fibrosis in patients are chronic bronchitis, pancreatic insufficiency, adolescent diabetes, pancreatitis, male sterility, and very rarely intestinal obstruction or liver cirrhosis. The mortality and morbidity of patients are dependent on the degree of bronchopulmonary involvement.

Research company's analysts estimation the Cystic Fibrosis market in Europe (EU) to grow at a Compound annual growth rate of ~35.1% over the time frame 2014-2019.

What is the scope of this report?

This business report contains the current situation and the growth perspectives of the Cystic Fibrosis market in Europe (EU) for the time frame 2015-2019. In this report, the market size is calculated from the revenue generated from the sales of different generic and branded therapies used in the treatment of cystic fibrosis containing:

• Small Molecules

• Biologics

Market research company's report, Cystic Fibrosis Sector in Europe 2015-2019, has been produced established on a comprehensive and detailed market studies with data coming from specialists of the sector. The analysis includes info from EU; it also encloses the market landscape of the Cystic Fibrosis market in Europe (EU) and its growth expectations over the upcoming years. This study also comprises conversations with top vendors operating in this segment.

Other main sellers

• For a full, in-depth list, view our market report

What are the ongoing market challenges?

• High Cost of Treatments

• For a full, exhaustive list, view our market report

How the market is going?

• growth in Public Awareness

• For a full, in-depth list, view our market report

What are the main questions answered?

• What will the market value be in 2019 and what will the increase rate be?

• What are the key market forecasts?

• What is driving this sector?

• What are the conditions to market growth?

• Who are the main vendors in this market environment?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Amrita helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Cystic Fibrosis Therapeutics Market (By Major Marketed Products, Pharmacological Class, & Geography) and Pipeline Analysis – Global Forecast to 2024

Cystic Fibrosis Therapeutics Market (By Major Marketed Products, Pharmacological Class, & Geography) and Pipeline Analysis – Global Forecast to 2024

  • $ 1400
  • Industry report
  • October 2017
  • by Igate Research

The market for Cystic Fibrosis Therapeutics is anticipated to grow with double digit CAGR during the forecasting period. Cystic fibrosis is among the most common life-threatening genetic disorders worldwide. ...

Exocrine Pancreatic Insufficiency Global Clinical Trials Review, H2, 2017

Clinical Research in Exocrine Pancreatic Insufficiency in H2, 2017

  • $ 2500
  • Industry report
  • August 2017
  • by GlobalData

Exocrine Pancreatic Insufficiency Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Exocrine Pancreatic Insufficiency Global Clinical Trials Review, H2, 2017" provides ...

Bronchiectasis Global Clinical Trials Review, H1, 2017

Clinical Research in Bronchiectasis in H1, 2017

  • $ 2500
  • Industry report
  • May 2017
  • by GlobalData

Bronchiectasis Global Clinical Trials Review, H1, 2017SummaryGlobalData’s clinical trial report, “Bronchiectasis Global Clinical Trials Review, H1, 2017" provides an overview of Bronchiectasis clinical ...


ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.